Cost-opportunity analysis in clinical oncology: From the 'wild far-west' to a correct integration of the disciplines, avoiding the 'war of the worlds' [3]

Annals of Oncology

Volumn 17, Issue 5, 2006, Pages 876-877

  Tassinari, D ^a   Poggi, B ^a   Fantini, M ^a   Tamburini, E ^a   Nicoletti, S ^a   Sartori, S ^b  

^a City Hospital   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; RITUXIMAB; TRASTUZUMAB;

BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HODGKIN DISEASE; HUMAN; LETTER; MEDICAL DECISION MAKING; ONCOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS; NEOPLASMS; PALLIATIVE CARE;

EID: 33646178390     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj086     Document Type: Letter

References (9)

1. Colleoni M, Gelber S, Goldhirsch A. Treatment of advanced breast cancer: the good, the bad and the ugly. Ann Oncol 2005; 16: 1219-1221.
2. Bocci G, Tuccori M, Emmenegger U et al. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005; 16: 1243-1252.
3. Bosanquet N, Sikora K. The economics of cancer care in the UK. Lancet Oncol 2004; 5: 568-574.
4. Chirikos TN. Cancer economics: On variations in the costs of treating cancer. Cancer Control 2002; 9: 59-66.
5. ASCO Special Article. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996; 14: 671-679.
6. Williams G, Pazdur R. Endpoints for Cancer Drug Approval: Regulatory Considerations. American Society of Clinical Oncology Educational Book. Alexandra, VA: American Society of Clinical Oncology, 2005; 482-486.
7. Meropol NJ, Desmond-Hellmann S, Tunis S et al. Can Society Afford State-of-the-art Cancer Treatment? American Society of Clinical Oncology Educational Book. Alexandra, VA: American Society of Clinical Oncology, 2005; 473-480.
8. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003; 22: 151-185.
9. NCI-ASCO Special Article. Integrating economic analysis into cancer clinical trials: The National Cancer Institute-American Society of Clinical Oncology economic workbook. J Natl Cancer Inst Monogr 1998; 24: 1-28.